Adoption of income statement and balance sheet as well as group income statement and group balance sheet

The AGM resolved to adopt the presented income statement and balance sheet as well as the group income statement and group balance sheet.

Appropriation of earnings

The AGM resolved to carry forward the profit available at the disposal of the AGM in accordance with the board’s proposal and thus no dividends are paid for the financial year 2021.

Discharge from liability

The AGM resolved on the discharge from liability for board members and the CEO.

Determination of number of board members, deputy board members and the number of auditors and determination of fees to the board and auditors

The AGM resolved that, for the period until the next AGM is held, board is to be comprised of seven members and two deputies and that fees to the board are to be paid in the amount of SEK 193,200 to the chairman (corresponding to four price base amounts), with SEK 96,600 to each of the other board members (corresponding to two price base amounts) and with SEK 48,300 to each of the deputy board members (corresponding to one price base amount). Furthermore, the AGM resolved that for the period until the end of the next AGM, one auditor shall be appointed and that fees to the auditors shall be paid according to invoices approved by the company.

Election of board members, deputies and auditors

The AGM resolved to re-elect Catharina Bäärnhielm, Björn Dahlöf, Sverker Jern, Rein Piir, Anders Svensson, and Klementina Österberg as board members and that Lena Mårtensson be elected as a new board member. The AGM further resolved that Niklas Bergh be re-elected as deputy board member and that Jonas Faijerson Säljö be elected as a new deputy board member. The AGM resolved to re-elect Frejs Revisorer AB as the company’s auditor. Frejs Revisorer AB has informed the company that Mikael Glimstedt will continue as principal auditor.

Principles for the Nomination Committee

The AGM resolved, in accordance with the board’s proposal, to establish a Nomination Committee and adopt the proposed principles for the Nomination Committee.

The complete proposal of the board is available on the company’s website (www.cerenoscientific.com).

Resolution on amendment of the Articles of Association

The AGM resolved, in accordance with the board’s proposal, to adopt new Articles of Association.

The complete proposal of the board is available on the company’s website (www.cerenoscientific.com).

Resolution on authorisation for the Board to decide on the new issue of shares and/or warrants and/or convertibles

The AGM resolved, in accordance with the board’s proposal of the Board of Directors, to authorize the board to resolve, on one or several occasions, on issue of shares and/or warrants and/or convertibles during the time until the next AGM.

The complete proposal of the board is available on the website of the company (www.cerenoscientific.com).

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.